Urokinase plasminogen activator protects cardiac myocytes from oxidative damage and apoptosis via hOGG1 induction

Philipp J. Hohensinner(Ludwig Boltzmann Institute for Age Research), Johann Wojta(Medical University of Vienna), Andreas Zuckermann(Medical University of Vienna), Nikol Margit Takács(Medical University of Vienna), Stefan Pfaffenberger(Medical University of Vienna), Kurt Huber(Sigmund Freud Privatuniversität Wien), Christoph Kaun(University of Vienna), Konstantin A. Krychtiuk(Ludwig Boltzmann Institute for Cardiovascular Research), A.Z. Aliabadi(Medical University of Vienna), Barbara Thaler(Medical University of Vienna)
APOPTOSIS
June 22, 2017
10.1007/s10495-017-1388-9
Cited by 23

Related Papers

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
|Circulation|2011|1.1k
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
|The Lancet|2018|793
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755
Polar secretion of endothelin-1 by cultured endothelial cells.
|Journal of Biological Chemistry|1992|645